Skip to main content
. 2010 Jul 7;84(19):10169–10181. doi: 10.1128/JVI.00568-10

TABLE 3.

Pathology development in HI-infected/immunotherapy-treated mice

Group Wk 3
Wk 20
Survival Survival % Hematocrit Spleen mass (g)
HI infected/667 MAb treated 20/20a 20/20a 50 ± 1.3 0.06 ± 0.01
HI infected/672 MAb treated 11/11a 0/11a 38 ± 2.02 1.02 ± 0.18
HI infected/667 F(ab′)2 treated 18/18a 0/18a 26 ± 1.7 1.8 ± 0.3
a

Number of mice in each group.